Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

adavosertib MeSH Supplementary Concept Data 2025


MeSH Supplementary
adavosertib
Unique ID
C549567
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C549567
Entry Term(s)
2-allyl-1-(6-(2-hydroxy-2-propanyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1,2-dihydro-3H-pyrazolo(3,4-d)pyrimidin-3-one
3H-pyrazolo(3,4-D)pyrimidin-3-one, 1,2-dihydro-1-(6-(1-hydroxy-1-methylethyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-
AZD 1775
AZD-1775
AZD1775
MK 1775
MK-1775
MK1775
Pharm Action
Enzyme Inhibitors
Registry Numbers
K2T6HJX3I3
0
Heading Mapped to
*Pyrazoles
*Pyrimidinones
Frequency
170
Note
a Wee1 kinase inhibitor; structure in first source
Source
Mol Cancer Ther 2009 Nov;8(11):2992-7000
Date of Entry
2010/05/26
Revision Date
2019/10/30
adavosertib Preferred
MK-1775 Narrower
AZD-1775 Narrower
page delivered in 0.002s